Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus

Sanofi is letting go of a genetic kidney disease therapy under development with Regulus Therapeutics after getting a peak at an interim analysis.

Development will be shut down for the anti-microRNA 21 oligonucleotide called lademirsen, which was being tested in patients with a genetic disease called Alport syndrome. Patients experience progressive loss of kidney function, hearing loss and eye abnormalities.